Treatment of Dry Eye With Supplements
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01364311|
Recruitment Status : Withdrawn
First Posted : June 2, 2011
Last Update Posted : April 15, 2015
Dry eye syndrome (DES) is a highly prevalent ocular condition inducing an inflammatory response on the ocular surface. Common symptoms include ocular discomfort, visual impairment and instability of the tear film with potential damage to the ocular surface.
In addition, an intact tear film is important to provide a smooth optical surface, to act as a barrier to pathogens, to nourish the epithelial cells of the ocular surface and to prevent exsiccation. Alterations in the tear film composition, which can have their origin in several conditions, lead to tear film hyperosmolarity or instability resulting in DES.
Regardless of the cause of DES, chronic dryness of the ocular surface leads to an increased susceptibility to oxidative stress, which is triggered by reactive oxygen species (ROS). This results in cell damage and activation of the immune system, keeping up inflammatory processes . In order to prevent ROS damage, several micronutrients such as vitamin C, E, and certain carotenoids, omega-3 free fatty acids, flavonoids and minerals have been used because of their antioxidant capacities.
Based on this knowledge the potential of these antioxidant dietary supplements has been discussed as a treatment option for DES. Preliminary data support the hypothesis that antioxidant supplementations, in particular, supplementation with omega 3 fatty acids may be beneficial for patients with DES.
The purpose of the present study is to test the hypothesis that treatment with dietary supplements improves subjective and objective symptoms of DES.
|Condition or disease||Intervention/treatment||Phase|
|Dry Eye Syndromes||Dietary Supplement: Vitamac® Tag and Nacht capsules||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Treatment of Dry Eye With Supplements|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
- Dietary Supplement: Vitamac® Tag and Nacht capsules
Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.
Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks
- Improvement of subjective symptoms of dry eye syndrome [ Time Frame: 12 weeks ]
- Break up time (BUT) [ Time Frame: 12 weeks ]
- Visual Acuity [ Time Frame: 12 weeks ]
- Tear film osmolarity [ Time Frame: 12 weeks ]
- OSI (Objective Scattering Index) [ Time Frame: 12 weeks ]
- Schirmer I test [ Time Frame: 12 weeks ]
- Staining of the cornea with fluorescein [ Time Frame: 12 weeks ]
- Impression cytology [ Time Frame: 12 weeks ]
- Tear cytokines/chemokines [ Time Frame: 12 weeks ]
- Data from patient diary how often Hylo-Comod® eye drops were used [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01364311
|Department of Clinical Pharmacology, Medical University Vienna|
|Vienna, Austria, 1090|
|Principal Investigator:||Doreen Schmidl, MD||Department of Clinical Pharmacology,Medical University of Vienna|